Funding

PART B: VALORISATION PLAN

SECTION I: ESTIMATION OF COSTS

 

1

Taking into account the rest of the cost evaluation please provide an overall estimation of the total costs for full deployment/production of the R & D result.
 
… in terms of IPR protection
A software can’t be protected by a patent.

Within European Union member states, indeed, a computer-implemented inventions which only solve a business problem using a computer, rather than a technical problem, are considered unpatentable as lacking an inventive step.

Software is protected as works of literature under the Berne Convention. This allows the creator to prevent another entity from copying the program and there is generally no need to register code in order for it to be copyrighted.

So, in this case the protection does not provide significant costs.

 

…in terms of product development
 

In terms of product development, CRO needs a software developer for 1/3 of his/her time(15.000 €).

 

 

…in terms of mass production
 

There are not specific mass production costs

 

… in terms of marketing
 

There are not marketing costs

 

 

2

Based on the above assessment as well as the marketing information please provide the correct estimation of the price for R&D product in correlation with costs

Year 1

Year 2

Year 3

Year 4

Year 5

Fixed costs

Personnel

35.000

35.000

35.000

Other running costs

5.000

Marketing costs

TOTAL EXPECTED COSTS

40.000

35.000

35.000

Price per Unit

1.000

1.000

1.000

Type of Unit

Number of Units

20

40

80

TOTAL Expected Revenues

20.000

40.000

80.000

CASH FLOW REQUIRED (REVENUES-COSTS)

(15.000)

5.000

45.000

TOTAL CAPITAL required for five years

15.000

 

SECTION 2: QUALITATIVE FACTORS

 

4

Dimension of identified target groups
 
 

The target market of MnemoKairos database could be the hospital field.

In Italy there are more than 1.500 private and public hospitals, so we can estimate more than 150.000 units all around the world.

A potential market can be of about 500 users all over the world.

 

 

 

 

 

6

Evaluation of financial Risks for R&D result
 

The project has no particular financial risks, because it doesn’t need any investment in fixed assets.

 

 

 

 

SECTION 3: IDENTIFICATION OF FINANCING SOURCES

After evaluating all the above mentioned criteria, please tick the best financing source for the achievement of R&D result (i.e. own capitals, banking credits, venture capital, business angels, etc)

 

  1. 1.  European Funding

Define relevance of the product with the following potential funding sources and comment

1. …FP7

2. …FP8

3.

4.

2      National Funding

 

1. … LR 4/2005 (Friuli Venezia Giulia regional law for the development of innovative projects whose objective is the company growth)

2. …LR 26/2005 (Friuli Venezia Giulia regional law on innovation)

3.

4.

3      Private funding

 

1. …Business Angel/Venture capitalist

2.

3.

4      Other

 

 

 

SECTION 3: FINAL EVALUATION

It is requested a final evaluation considering the funding opportunities you believe most suitable for the exploitation of the R&D result, considering the possibility of the creation of a spin-off, further research, in particular, a cost/benefit analysis and a financial projection for the R&D result, type of collaboration identified (i.e. Licensing Agreement, Technical Cooperation, Joint Venture, Manufacturing Agreement, Commercial Agreement with Technical Assistance, Creation of a spin-off, Joint further development)…
 

CRO has already developed the database and could verify the opportunity of selling it to other institutes and hospitals all over the world.

Considering that this project doesn’t need further relevant resources, probably is not recommended the creation of a spin off.

In any case it should be analyze the opportunity of partnerships and the funding opportunities in order to complete the database development.

 

 

 

 

Decision of evaluation (Please tick  as appropriate)

 

The R&D has a high potential of exploitation

þ

The R&D result needs minor revisions

The R&D result needs moderate revisions

The R&D result needs major revisions

The R&D result has no potential of exploitation

 

 

Bookmark the permalink. Follow any comments here with the RSS feed for this post. Post a comment or leave a trackback: Trackback URL.

Post a Comment

You must be logged in to post a comment.

Request a proposal

Valorisation Plan Authors

Related Documents

There in no related documents

Visit the other applications of the INTERVALUE Platform: R&D Repository | IP Agreements

© 2009-2010 INTERVALUE Project